REG - Citigroup GM HK Takeda Pharma.Co.Ltd - Form 8 (DD) - TAKEDA PHARMACEUTICAL

Takeda Pharmaceutical CoAnnouncement

11/12/2018 13:30

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20181211:nRSK1384Ka

RNS Number : 1384K
Citigroup Global Markets Hong Kong
11 December 2018
 
 
 
FORM 8 (DD)
 
PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT
(INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)
Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code")
 
1.         KEY INFORMATION
 
 (a) Full name of discloser:                                                     Citigroup Global Markets Hong Kong
 (b) Owner or controller of interests and short positions disclosed, if
 different from 1(a):
      The naming of nominee or vehicle companies is insufficient.  For a
 trust, the trustee(s), settlor and beneficiaries must be named.
 (c) Name of offeror/offeree in relation to whose relevant securities this form  Takeda Pharmaceutical Company Limited
 relates:
      Use a separate form for each offeror/offeree
 (d) Status of person making the disclosure:                                     Corporate Broker to Shire Plc
      e.g. offeror, offeree, person acting in concert with the
 offeror/offeree (specify name of offeror/offeree)
 (e) Date dealing undertaken:                                                    10 December 2018
 (f)  In addition to the company in 1(c) above, is the discloser making          No
 disclosures in respect of any other party to the offer?
      If it is a cash offer or possible cash offer, state "N/A"
 
2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE
 
If there are positions or rights to subscribe to disclose in more than one
class of relevant securities of the offeror or offeree named in 1(c), copy
table 2(a) or (b) (as appropriate) for each additional class of relevant
security.
 
(a)        Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates following the dealing
 
 Class of relevant security:                                          Ordinary
                                                                      Interests       Short positions
                                                                      Number   %      Number    %
 (1) Relevant securities owned and/or controlled:                     334,928  0.04   13,800    0.00
 (2) Cash-settled derivatives:                                        0        0.00   0         0.00
 (3) Stock-settled derivatives (including options) and agreements to  0        0.00   0         0.00
 purchase/sell:
                                                                      334,928  0.04   13,800    0.00
      TOTAL:
 
All interests and all short positions should be disclosed.
 
 Details of any open stock-settled derivative positions (including traded
options), or agreements to purchase or sell relevant securities, should be
given on a Supplemental Form 8 (Open Positions).
 
Details of any securities borrowing and lending positions or financial
collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).
 
(b)        Rights to subscribe for new securities (including directors'
and other employee options)
 
 Class of relevant security in relation to which subscription right exists:
 Details, including nature of the rights concerned and relevant percentages:
 
3.         DEALINGS BY THE PERSON MAKING THE DISCLOSURE
 
Where there have been dealings in more than one class of relevant securities
of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as
appropriate) for each additional class of relevant security dealt in.
 
The currency of all prices and other monetary amounts should be stated.
 
(a)        Purchases and sales
 
(i)         Party to an offer or person acting in concert (except for
a principal trader in the same group as a connected adviser)
 
 Class of relevant security  Purchase/sale  Number of securities  Price per unit (HKD)
                             Purchase       400                   3,801.50
                             Purchase       600                   3,802.6667
                             Purchase       1,500                 3,796.1333
                             Purchase       2,300                 3,778.6522
                             Purchase       5,200                 3,779.4423
 
(ii)        Principal trader where the sole reason for the connection
is that the principal trader is in the same group as a connected adviser
 
 Class of relevant security  Purchases/ sales  Total number of securities  Highest price per unit paid/received  Lowest price per unit paid/received
 
(b)        Cash-settled derivative transactions
 
 Class of relevant security  Product description  Nature of dealing  Number of reference securities  Price per unit (EUR)
                             e.g. CFD
 
 
(c)        Stock-settled derivative transactions (including options)
 
(i)         Writing, selling, purchasing or varying
 
 Class of relevant security  Product description e.g. call option  Writing, purchasing, selling, varying etc.  Number of securities to which option relates  Exercise price per unit  Type                           Expiry date  Option money paid/ received per unit
                                                                                                                                                                                      e.g. American, European etc.
 
(ii)        Exercise
 
 Class of relevant security  Product description  Exercising/ exercised against  Number of securities  Exercise price per unit
                             e.g. call option
 
(d)        Other dealings (including subscribing for new securities)
 
 Class of relevant security  Nature of dealing               Details  Price per unit (if applicable)
                             e.g. subscription, conversion
 
 
4.         OTHER INFORMATION
 
(a)        Indemnity and other dealing arrangements
 
 Details of any indemnity or option arrangement, or any agreement or
 understanding, formal or informal, relating to relevant securities which may
 be an inducement to deal or refrain from dealing entered into by the party to
 the offer or person acting in concert making the disclosure and any other
 person:
 Irrevocable commitments and letters of intent should not be included.  If
 there are no such agreements, arrangements or understandings, state "none"
 
(b)        Agreements, arrangements or understandings relating to
options or derivatives
 
 Details of any agreement, arrangement or understanding, formal or informal,
 between the party to the offer or person acting in concert making the
 disclosure and any other person relating to:
 (i)  the voting rights of any relevant securities under any option; or
 (ii) the voting rights or future acquisition or disposal of any relevant
 securities to which any derivative is referenced:
 If there are no such agreements, arrangements or understandings, state "none"
 
 
 
(c)        Attachments
 
Are any Supplemental Forms attached?
 
 Supplemental Form 8 (Open Positions)  NO
 Supplemental Form 8 (SBL)             NO
 
 Date of disclosure:  11 December 2018
 Contact name:        Cathal McKenna
 Telephone number:    +44 2890 409544
 
Public disclosures under Rule 8 of the Code must be made to a Regulatory
Information Service and must also be emailed to the Takeover Panel at
monitoring@disclosure.org.uk (mailto:monitoring@disclosure.org.uk) .  The
Panel's Market Surveillance Unit is available for consultation in relation to
the Code's dealing disclosure requirements on +44 (0)20 7638 0129.
 
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
(http://www.thetakeoverpanel.org.uk) .
 
 
 
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.